Sugi Predict

Sugi Predict / Compounds / SCHEMBL1922020

SCHEMBL1922020

SCHEMBL1922020

O=Cc1cc(F)c(Cl)cc1O

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 9/20 0.55
▸ TDP1 Q9NUW8 2/20 0.43
▸ MEN1 O00255 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ RAB9A P51151 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ TYR P14679 2/20 0.37
▸ TRIM24 O15164 1/20 0.37
▸ TRIM33 Q9UPN9 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL692164 0.94 ERN1 (0.48) ERN1TDP1MEN1NPC1ALDH1A1
SCHEMBL31183326 0.94 ERN1 (0.48) ERN1TDP1MEN1NPC1ALDH1A1
SCHEMBL31183331 0.94 ERN1 (0.48) ERN1TDP1MEN1NPC1ALDH1A1
SCHEMBL1922524 0.84 ERN1 (0.61) ERN1TDP1MEN1NPC1ALDH1A1
SCHEMBL31442964 0.84 ERN1 (0.61) ERN1TDP1MEN1NPC1ALDH1A1
SCHEMBL1053807 0.83 ERN1 (0.50) ERN1TDP1TRIM24TRIM33HPGD
SCHEMBL25240603 0.82 ERN1 (0.59) ERN1TDP1MEN1NPC1ALDH1A1
SCHEMBL3404206 0.81 ERN1 (0.52) ERN1TYRTRIM24TRIM33
SCHEMBL12813947 0.79 ERN1 (0.50) ERN1TYRTRIM24TRIM33
SCHEMBL31114205 0.79 ERN1 (0.50) ERN1TYRTRIM24TRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111943973-B Bimetallic complex of phenoxyimine ligand framework, preparation method and application 万华化学集团股份有限公司 2023-06-09 — — CN claimed
CN-111943973-A Bimetallic complex of phenoxy imine ligand skeleton, preparation method and application 万华化学集团股份有限公司 2020-11-17 — — CN claimed
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES INC (US) 2025-12-25 — — US disclosed
US-12448388-B2 PRMT5 inhibitors and uses thereof GILEAD SCIENCES, INC. (US) 2025-10-21 — — US disclosed
US-12415771-B2 Compounds for the treatment of neuromuscular disorders NMD PHARMA A/S (DK) 2025-09-16 — — US disclosed
US-20250214976-A1 GPR35 MODULATORS AND USES THEREOF CROSSIGNAL THERAPEUTICS, INC. 2025-07-03 — — US disclosed
CN-114008012-B Compounds for the treatment of neuromuscular disorders NMD制药股份公司 2025-02-25 — — CN disclosed
EP-4504712-A1 GPR35 MODULATORS AND USES THEREOF Crossignal Therapeutics, Inc. (US) 2025-02-12 — — EP disclosed
CN-119137105-A GPR35 modulators and uses thereof 交信医药研发公司 2024-12-13 — — CN disclosed
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-11-14 — — US disclosed
WO-2024220917-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2024-10-24 — — WO disclosed
CN-102099334-A Novel compounds active as muscarinic receptor antagonists PFIZER LTD 2011-06-15 — — CN disclosed
EP-2328868-A1 NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS Pfizer Limited (GB) 2011-06-08 — — EP disclosed
WO-2010007561-A1 NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 2010-01-21 — — WO disclosed
WO-2010007561-A1 NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 2010-01-21 — — WO disclosed
WO-2010007552-A1 NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 2010-01-21 — — WO disclosed
WO-2010007552-A1 NOVEL COMPOUNDS ACTIVE AS MUSCARINIC RECEPTOR ANTAGONISTS PFIZER LIMITED (GB) 2010-01-21 — — WO disclosed
US-20100016366-A1 Novel Compounds Active as Muscarinic Receptor Antagonists GLOSSOP PAUL ALAN 2010-01-21 — — US disclosed
US-20100016366-A1 Novel Compounds Active as Muscarinic Receptor Antagonists GLOSSOP PAUL ALAN 2010-01-21 — — US disclosed
US-20100016366-A1 Novel Compounds Active as Muscarinic Receptor Antagonists GLOSSOP PAUL ALAN 2010-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388585-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT1, PRMT5, PRMT6 ERN1 1112/4885TDP1 161/4885MEN1 730/4885
US-20100016366-A1 Novel Compounds Active as Muscarinic Receptor Antagonists CHRM3, CHRM2, CHRM5 ERN1 4491/4885TDP1 4456/4885MEN1 2208/4885
US-20240376110-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 ERN1 1469/4885TDP1 84/4885MEN1 406/4885
US-12448388-B2 PRMT5 inhibitors and uses thereof PRMT5, PRMT1, PRMT9 ERN1 1469/4885TDP1 84/4885MEN1 406/4885
US-20250214976-A1 GPR35 MODULATORS AND USES THEREOF GPR35, GPR34, GPR68 ERN1 4770/4885TDP1 4520/4885MEN1 3134/4885
US-12415771-B2 Compounds for the treatment of neuromuscular disorders RYR1, CACNB1, SMN1; SMN2 ERN1 2210/4885TDP1 202/4885MEN1 2853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.